This mendelian randomization analysis of individual-participant data estimated the association between changes in levels of low-density lipoprotein cholesterol (and other lipoproteins) and risk of cardiovascular events due to CETP variants, alone and in combination with HMGCR variants.
This commentary discusses a study published in JAMA Cardiology that examined the association between intensity of statin therapy in patients with atherosclerotic cardiovascular disease and all-cause mortality among patients in the Veterans Affairs health care system.
This study uses NHANES data to compare the numbers of US adults eligible for primary prevention statin treatment under USPSTF vs ACC/AHA guideline criteria.
This randomized clinical trial compares the effects of evolocumab vs placebo on change in percent atheroma volume among adult patients with angiographic coronary disease despite treatment with statins.
This Evidence Report and systematic review to support the 2016 US Preventive Services Task Force Recommendation Statement on use of statins for prevention of cardiovascular disease (CVD) summarizes published trial evidence about the benefits and harms of statins for primary CVD prevention.
This Recommendation Statement from the US Preventive Services Task Force recommends use of low- to moderate-dose statins for primary prevention in adults aged 40 to 75 years who have 1 or more CVD risk factors and a calculated CVD event risk of 10% or greater (B recommendation).
This Viewpoint summarizes the findings and limitations of clinical trial evidence regarding the benefits and risks of statins for primary prevention of atherosclerotic cardiovascular disease in persons older than 75 years.
This Viewpoint reviews the myths about and makes recommendations for statin treatment.
This Viewpoint discusses the role of implementation and translational science and digital platforms for improving population cardiovascular risk and advancing precision treatments in an era of intensive statin therapy and PCSK9 inhibitors.
This meta-analysis compares the association between lowering low-density lipoprotein cholesterol (LDL-C) and cardiovascular risk reduction for statin vs nonstatin therapies that lower LDL-C.
This study estimates the cost-effectiveness of adding proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors to statin therapy for patients with heterozygous familial hypercholesterolemia (FH) or atherosclerotic cardiovascular disease (ASCVD).
This systematic review to support the 2016 update of the US Preventive Services Task Force Recommendation Statement on screening for lipid disorders in children and adolescents summarizes published evidence about the effectiveness of routine screening, accuracy of screening tests and strategies, and potential screening harms.
You currently have no searches saved.